Skip to main content

Table 2 Description of currently ongoing AD prevention clinical trials

From: Alzheimer’s disease prevention: from risk factors to early intervention

Estimated enrolment 210 300 1150 3494 1340 1650
Target population/specific characteristics Autosomal dominant Alzheimer’s disease (ADAD) mutation carriers or persons that have a 50% chance of carrying an ADAD mutation Membership in PSEN1 E280A mutation carrier kindred Cognitively normal, positive brain amyloid PET Cognitively normal with genetic risk (TOMM40 and APOE genotype) Cognitively normal APOE-ε4 homozygous Cognitively normal positive amyloid
Age 18–80 years 30–60 years 65–85 years 65–83 years 60–75 years 60–85 years
Phase Phase II/III Phase II Phase III Phase III Phase II/III Phase II/III
Compound Gantenerumab
Crenezumab Solanezumab Pioglitazone CAD106
Mechanism Anti-Aβ antibodies Anti-Aβ antibody Anti-Aβ antibody PPAR-γ agonist Aβ vaccine
BACE inhibitor
BACE inhibitor
Status Ongoing, not recruiting Active, not recruiting Recruiting Active, not recruiting Recruiting Recruiting
Primary outcome Composite Cognitive Test Score Composite Cognitive Test Score Composite Cognitive Test Score Time to diagnosis of mild cognitive impairment (MCI) due to AD Time to diagnosis of MCI or dementia due to AD
Composite Cognitive Test Score
Composite Cognitive Test Score
Study duration 4 years 5 years 3 years 5 years 5 years 4.5 years
Trial identifier NCT01760005 NCT01998841 NCT02008357 NCT01931566 NCT02565511 NCT02569398
Expected completion December 2019 September 2020 October 2020 July 2019 August 2023 May 2023
  1. Source: (accessed May 2017) [45]
  2. A4 Anti-Amyloid Treatment in Asymptomatic Alzheimer’s study, Aβ amyloid beta, AD Alzheimer’s disease, API-ADAD Alzheimer’s Prevention Initiative for Autosomal Dominant Alzheimer’s Disease, API-GENERATION A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease, BACE Beta-secretase, DIAN Dominantly Inherited Alzheimer Network, EARLY An Efficacy and Safety Study of JNJ-54861911 in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia, PET Positron Emission Tomography, PPAR Peroxisome proliferator activated receptor, PSEN1 presenilin 1, TOMMORROW Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset